Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.400
-14.600-3.00%
Volume:329.98K
Turnover:155.18M
Market Cap:112.90B
PE:-285.12
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.66
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.07
PE(LYR):-285.12
PS:46.24

Loading ...

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

SKB BIO: DFZQ Disposes of Shares, Long Position Falls to 4.99%

HK Disclosure
·
Sep 04

SKB BIO: DFZQ Acquires Shares, Long Position Rises to 5.01%

HK Disclosure
·
Sep 04

HTF Fund Management Increases Stake in SKB BIO with Recent Share Purchase

Stock News
·
Sep 03

SKB BIO: China Universal Asset Management Acquires Shares, Long Position Rises to 5.01%

HK Disclosure
·
Sep 03

SKB BIO Monthly Return: No Share Capital Movement in August 2026, Public Float Compliance Affirmed

Bulletin Express
·
Sep 03

Movement Alert|SKB BIO Falls 3.4% in Regular Trading, Biotechnology Sector Under Broad Pressure

Market Focus
·
Aug 31

Movement Alert|SKB BIO Falls 3.16% in Regular Trading, Trading at HK$519.5

Market Focus
·
Aug 24

Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) After Profitability And Oncology Progress Looks Undervalued

Simply Wall St.
·
Aug 22

Historic Breakthrough in mRNA Cancer Vaccines: E Fund Biotech ETF (03186) Taps Innovation Opportunities Across Hong Kong and US Markets

Stock News
·
Aug 20

SKB BIO Receives Price Target Increase to HK$642 with Buy Rating Maintained by BOCOM International

Deep News
·
Aug 20

Movement Alert|SKB BIO Rises 4.11% in Regular Trading, Multiple Investment Banks Raise Target Prices Boosting Market Confidence

Market Focus
·
Aug 20

China's Ascentage Pharma H1 Revenue Rises 29% on Lisaftoclax Ramp-up

Reuters
·
Aug 20

Earnings Update: Here's Why Analysts Just Lifted Their Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Price Target To HK$612

Simply Wall St.
·
Aug 20

Sino Biopharmaceutical H1 Revenue up 10.6% on Innovative Drug Sales

Reuters
·
Aug 19

BofA Securities Raises SKB BIO Price Target to HK$644.4, Projects Full-Year Profitability

Stock News
·
Aug 19

Movement Alert|SKB BIO Declines 3.04% in Regular Trading, Profit-Taking as Earnings Quality Questioned Over One-Time Items

Market Focus
·
Aug 19

China's GenScript Biotech H1 Revenue Rises on AI Drug Discovery

Reuters
·
Aug 18

Germany's Immatics Q2 Revenue Rises but Misses Estimates

Reuters
·
Aug 18

Sichuan Kelun-Biotech (SEHK:6990) Stock Rebound Meets Profit Quality Questions

Simply Wall St.
·
Aug 18